About Orgenesis
Orgenesis is a company based in Germantown (United States) founded in 2008.. Orgenesis has completed 3 acquisitions, including Koligo Therapeutics, MaSTherCell and Tissue Genesis. Orgenesis offers products and services including POCare Platform, Mobile Processing Units and Labs, POCare Therapies, POCare Technology, and POCare Network. Orgenesis operates in a competitive market with competitors including Enlivex Pharmaceuticals, TissueGene, Ori Biotech, Sernova and MaSTherCell, among others.
- Headquarter Germantown, United States
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Orgenesis, Inc.
-
Annual Revenue
$530 K-98.53as on Dec 31, 2023
-
Net Profit
$-55.36 M-271.82as on Dec 31, 2023
-
EBITDA
$-53.33 M-858.67as on Dec 31, 2023
-
Latest Funding Round
$2.34 M (USD), Post-IPO
Mar 04, 2024
-
Investors
Metalmark Capital
& 1 more
-
Employee Count
Employee Count
-
Investments & Acquisitions
Koligo Therapeutics
& 2 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Orgenesis
Orgenesis is a publicly listed company on the OTC with ticker symbol ORGS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Orgenesis
Orgenesis offers a comprehensive portfolio of products and services, including POCare Platform, Mobile Processing Units and Labs, POCare Therapies, POCare Technology, and POCare Network. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Provides pathway for affordable cell and gene therapy development.
Integrated system for closed-loop cell therapy production.
Develops and validates gene therapy options for patients.
Automates harmonized therapy manufacturing processes.
Facilitates global partnerships for therapy distribution.
Unlock access to complete
Unlock access to complete
Funding Insights of Orgenesis
- Total Funding Total Funding
- Total Rounds 11
- Last Round Post-IPO — $2.3M
-
First Round
First Round
(13 May 2013)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2024 | Amount | Post-IPO - Orgenesis | Valuation |
investors |
|
| May, 2023 | Amount | Post-IPO - Orgenesis | Valuation |
investors |
|
| Nov, 2022 | Amount | Post-IPO - Orgenesis | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Orgenesis
Orgenesis has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Metalmark Capital and Kodiak Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Metalmark Capital is focused on growth equity investments in middle-market companies.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Orgenesis
Orgenesis has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Koligo Therapeutics, MaSTherCell and Tissue Genesis. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Developer of trans-formative cell therapies for treating chronic pancreatitis and Type I diabetes
|
2016 | ||||
|
Services for cell therapy development and manufacturing are provided.
|
2011 | ||||
|
Stem cell therapeutics for vascular disease
|
2001 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Orgenesis
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Orgenesis Comparisons
Competitors of Orgenesis
Orgenesis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Enlivex Pharmaceuticals, TissueGene, Ori Biotech, Sernova and MaSTherCell, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Autologous and allogeneic cell immunotherapies are developed for autoimmune conditions.
|
|
| domain | founded_year | HQ Location |
Regenerative cell therapies for orthopedic diseases are developed.
|
|
| domain | founded_year | HQ Location |
Software development services are provided for the biopharma sector.
|
|
| domain | founded_year | HQ Location |
Regenerative medicine to deliver proteins and hormones for disease treatment
|
|
| domain | founded_year | HQ Location |
Services for cell therapy development and manufacturing are provided.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Orgenesis
Frequently Asked Questions about Orgenesis
When was Orgenesis founded?
Orgenesis was founded in 2008 and raised its 1st funding round 5 years after it was founded.
Where is Orgenesis located?
Orgenesis is headquartered in Germantown, United States.
What is the annual revenue of Orgenesis?
Annual revenue of Orgenesis is $530K as on Dec 31, 2023.
What does Orgenesis do?
Orgenesis was founded in 2008 and is headquartered in Germantown, United States. Operations focus on the biotechnology sector, where cell and gene therapies are developed to address various disorders. The pipeline encompasses treatments such as ORGCAR19 for lymphoma, MOTC for melanoma, RanTop HPV for genital warts and anal dysplasia, Kyslecel for chronic pancreatitis, Cartil-S for osteoarthritis, and additional candidates.
Who are the top competitors of Orgenesis?
Orgenesis's top competitors include Ori Biotech, Enlivex Pharmaceuticals and MaSTherCell.
What products or services does Orgenesis offer?
Orgenesis offers POCare Platform, Mobile Processing Units and Labs, POCare Therapies, POCare Technology, and POCare Network.
Is Orgenesis publicly traded?
Yes, Orgenesis is publicly traded on OTC under the ticker symbol ORGS.
How many acquisitions has Orgenesis made?
Orgenesis has made 3 acquisitions, including Koligo Therapeutics, MaSTherCell, and Tissue Genesis.
Who are Orgenesis's investors?
Orgenesis has 2 investors. Key investors include Metalmark Capital, and Kodiak Capital.
What is Orgenesis's ticker symbol?
The ticker symbol of Orgenesis is ORGS on OTC.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.